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Abstract 
New isocoumarins were prepared in an efficient way from 2-iodobenzoic acid 
derivatives and hept-1-yne in a Sonogashira reaction, followed by spontaneous 
cyclization. Catalytic hydrogenation gave the corresponding dihydro-
isocoumarins. A 4-chloroisocoumarin was prepared on an alternative pathway. 
Some of the new compounds showed moderate cytotoxic activities against a 
human leukemia cell line (HL 60).  
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Introduction 
Isocoumarins are a class of natural lactones with high structural diversity exhibiting a 
broad spectrum of biological activities [1]. Considerable work has been published over 
decades about their chemistry [2] and biology [3], and a number of natural and synthetic 
isocoumarins have been shown to exhibit significant cytotoxic and antitumor activities. 
Among these are numerous isocoumarins bearing various types of substituents (alkyl, 
alkenyl or aryl groups) at 3-position, as well as the dihydroisocoumarin AI-77-B (A, 
Figure  1). The latter one was first isolated from Bacillus pumilus, and shows in vitro 
cytotoxicity against human malignant A375-S2 and cervical cancer HeLa cells [4]. The 
paraphaeosphaerins (B) from cultures of Paraphaeosphaeria quadriseptana [5] are 
biogenetically related to the cytotoxic plant metabolites monocillin I and radicicol. NM-3 (C) 22 V.  Hampl  et al.:  
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is a synthetic analogue of cytogenin (E), and potentiates antineoplastic effects of other 
chemotherapeutic agents and inhibits angiogenesis [6]. This compound is in phase I 
clinical trials. The isocoumarin 185322 (D), an analogue of NM-3, is an inhibitor of 
microtubule assembly, and induces mitotic arrest and apoptosis of multiple myeloma cells 
[7]. Ochratoxin A (F), a mycotoxin from Aspergillus ochraceus shows nephrotoxic, 
hepatotoxic, carcinogenic and teratogenic properties in animals [8]; recently the European 
Pharmacopoeia introduced a limit test for ochratoxin A in plant material (Method 2.8.22). 
Scoparine A (G) was isolated from the North African medical plant Pituranthos scoparius 
[9]. 
The biological activities of the abovementioned and other isocoumarins and 
dihydroisocoumarins [10,  11] make this class of compounds interesting leads for 
development of new anticancer drugs.  
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Fig. 1.  Structures of AI-77-B (A), paraphaeosphaerin A (B), NM-3 (C), 185322 (D), 
cytogenin (E), ochratoxin A (F), and scoparine A (G). 
In a previous work [12] we prepared a number of isocoumarins and dihydroisocoumarins 
bearing alkyl and hydroxyalkyl residues at C-3 using a one-pot procedure originally 
described by Lia and Cheng [13]. Since these products showed only moderate cytotoxic 
activities, we assumed that additional functional groups at the bicyclic core should be of 
great importance. An isocoumarin with an isopentyl residue at C-3 was the most cytotoxic 
one in the previous investigations. This prompted us to investigate the influence of 
additional lipophilic substituents like halogens (cf. F) and methyl (cf. D) located at various 
positions of the ring system on the cytotoxicity of 3-alkyl(dihydro)isocoumarins. 
   Substituted Isocoumarins and Dihydroisocoumarins  23 
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Results and Discussion 
Chemistry 
The isocoumarins 2a–2d were prepared in poor to good yields in one pot reactions starting 
from commercially available 2-iodobenzoic acid derivatives 1a–d and hept-1-yne involving 
Sonogashira cross coupling reactions in the presence of zinc chloride [13]. The 
isocoumarins 2a, 2b [14] and 2d were further hydrogenated under palladium catalysis to 
give the corresponding dihydroisocoumarins 3a, 3b and 3d (Scheme 1). Hydrogenation of 
2c did not appear promising due to the risk of reductive dechlorination. 
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Sch. 1.   a: Triethylamine, ZnCl2, Pd(PPh3)2Cl2, DMF, 100 °C, 24 h ; b: H2, Pd/C, 
methanol, 25 °C, 12 h.  
The 4-chloroisocoumarin 5 was prepared in a different manner. Methyl 2-iodobenzoate 
(1e) was reacted in a Sonogashira reaction with hept-1-yne (in the absence of zinc 
chloride) [15,  16] to give the alkyne 4. Treating 4 with 2 equivalents of CuCl2 and a 
catalytic amount of N,N-dicyclohexylammonium chloride [17] resulted in cyclization to the 
chlorinated isocoumarin 5 (Scheme 2). 
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Sch. 2.   a: Pd(PPh3)2Cl2, CuI, N-ethyl-N,N-dimethylamine, DMF, 25 °C, 12 h; b: CuCl2, 
N,N-dicyclohexylammonium chloride, 1,2-dichloroethane, 80 °C, 12 h. 
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Biology 
The resulting isocoumarins and dihydroisocoumarins were tested for their cytotoxic activity 
in a MMT assay using the HL 60 leukemia cell line [18, 19]. The results are shown in 
Table 1. Since we had found some correlation of the cytotoxic activities with lipophilicity in 
previous investigations on isocoumarins [12], we also calculated the log P values of the 
new compounds. 
Tab. 1.   Cytotoxicity of the products against HL 60 cell line and calculated partition 
coefficients log P (calculated with Chem Draw Ultra 10, Cambridge Soft). 
Compound IC50 [µM]  log P 
2a  ≥100 3.32 
2b  58 3.48 
2c  ≥100 3.88 
2d  ≥100 3.81 
3a  49 3.89 
3b  63 3.48 
3d  103 4.38 
4  >1000 4.28 
5  ≥100 4.74 
cisplatin  5  
 
Discussion 
Among the five isocoumarins and three dihydroisocoumarins described here, four 
compounds, the fluorinated isocoumarin 2b and the dihydroisocoumarins 3a, 3b and 3d, 
showed measurable, albeit very poor cytotoxic activity. No clear tendency for higher 
acitivity of one of the two structural subtypes (2 versus 3) can be deduced from these 
results. Since the log P values of all tested compounds are in the same range, influences 
of lipophilicity on cytotoxic activity cannot be deduced as well.  
In conclusion, isocoumarins and dihydroisocoumarins containing exclusively lipophilic 
residues at both rings show significantly decreased cytotoxic activities compared to 
established analogues (AI-77-B (A): 0.2 to 0.4 µM against A375-S2 and HeLa cells [4], 
ochratoxin A (F) and stereoisomers thereof: 0.3 to 5 µM against Hep G2 cells [20]) 
containing additional polar groups (especially hydroxyl groups) at the benzenoid ring. 
For obtaining isocoumarins with significant cytotoxicity the presence of polar groups at the 
ring system seems to be indispensible. 
Experimental 
Elemental analysis: Heraeus CHN Rapid; IR spectra: Perkin-Elmer FT-IR Paragon 1000; 
MS (EI, 70 eV): Hewlett Packard MS-Engine; HRMS: Jeol Mstation 700; NMR: Jeol GSX 
400 (
1H: 400 MHz, 
13C: 100 MHz); flash column chromatography (FCC): Kieselgel 60 
(230–400 mesh, E. Merck, Darmstadt).    Substituted Isocoumarins and Dihydroisocoumarins  25 
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General procedure I: Synthesis of isocoumarins 2a–d 
Pd(PPh3)2Cl2 (0.140 g, 0.20 mmol) and ZnCl2 (0.496 g, 4.0 mmol) were added under N2 
atmosphere to a solution of aryl iodide (2.0 mmol), hept-1-yne (0.577 g, 6.0 mmol), and 
triethylamine (10 mmol) in DMF (2 mL). The suspension was heated at 100 °C for 24 h. 
The components of the suspension were separated by flash column chromatography 
(n-hexane/ethyl acetate). 
General procedure II: Preparation of dihydroisocoumarins 3a,b,d  
Pd on charcoal (10%) was added to a solution of the isocoumarin in methanol (20 mL). 
The suspension was stirred for 12 h under H2 atmosphere at ambient pressure, then the 
catalyst was filtered off, and the residue was washed with methanol. The combined 
organic layers were evaporated, and the residue was purified by FCC (n-hexane/ethyl 
acetate). 
3-Pentylisochromen-1-one (2a) 
Prepared following General procedure I from 0.496 g (2.0 mmol) 2-iodobenzoic acid to 
give 310 mg (71 %) as a pale yellow oil. MS (m/z, %): 216 ([M]
+·, 34), 160 (36), 118 (100). 
IR (KBr), ν (cm
−1): 2933, 2857, 1716, 1652, 1459, 1176, 769, 705, 592. 
1H NMR (400 MHz, 
CDCl3): δ (ppm) 0.90 (t, J = 7.5 Hz, 3 H, H-5’), 1.35 (m, 4 H, H-3’, H-4’), 1.70 (m, 2 H, H-
2’), 2.51 (t, J = 7.5 Hz, 2 H, H-1’), 6.26 (s, 1 H, H-4), 7.34 (d, J = 8.1 Hz, 1 H, H-5), 7.43 
(dd, J1 = J2 = 8.1 Hz, 1 H, H-7), 7.66 (dd, J1 = J2 = 8.1 Hz, 1 H, H-6), 8.24 (d, J = 8.1 Hz, 1 
H, H-8). 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.92 (C-5’), 22.34 (C-4’), 26.55 (C-2’), 
31.13 (C-3’), 33.45 (C-1’), 102.83 (C-4), 120.06 (C-8a), 127.48 (C-7), 129.45 (C-5), 129.46 
(C-8), 134.67 (C-6), 137.60 (C-4a), 158.28 (C-3), 163.12 (C-1). HRMS: Calcd. for 
C14H16O2: 216.1150. Found: 216.1100.  
8-Fluoro-3-pentyl-1H-isochromen-1-one (2b) [14] 
Prepared following General procedure I from 0.532 g (2.0 mmol) 6-fluoro-2-iodobenzoic 
acid to give 39 mg (9 %) as a brown oil. MS (m/z, %): 234 ([M]
+·, 19), 178 (24), 136 (100), 
107 (30). IR (KBr), ν (cm
−1): 2956, 2929, 2859, 1731, 1654, 1600, 1562, 1469, 1419, 1378, 
1321, 1272, 1240, 1201, 1149, 1087, 1054, 1031, 971, 923, 894, 831, 773, 719, 678, 651, 
570, 557. 
1H NMR (400 MHz, CDCl3) δ (ppm): 0.91 (t, J = 7.7 Hz, 3 H, H-5’), 1.35 (m, 4 H, 
H-3’, H-4’), 1.70 (m, 2 H, H-2’), 2.50 (t, J = 7.7 Hz, 2 H, H-1’), 6.23 (d, J = 2.3 Hz, 1 H, H-
4), 7.12 (m, 2 H, H-5, H-7), 7.61 (m, 1 H, H-6). HRMS: Calcd. for C14H15O2F: 234.1056. 
Found: 234.10594. Anal. Calcd. for C14H15O2F: C, 71.78; H, 6.45. Found: C, 72.27; H, 
7.66.  
6-Chloro-3-pentyl-1H-isochromen-1-one (2c) 
Prepared following General procedure I from 0.565 g (2.0 mmol) 4-chloro-2-iodobenzoic 
acid to give 75 mg (15 %) as a brown oil. MS (m/z, %): 252 ([M]
+·, 13), 250 ([M]
+·, 35), 194 
(45), 152 (100), 123 (20). IR (KBr), ν (cm
−1): 2956, 2929, 2859, 1774, 1745, 1660, 1614, 
1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 808, 777, 728, 688, 669. 
1H NMR 
(400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.6 Hz, 3 H, H-5’), 1.35 (m, 4 H, H-3’, H-4’), 1.70 
(m, 2 H, H-2’), 2.52 (t, J = 7.6 Hz, 2 H, H-1’), 6.18 (s, 1 H, H-4), 7.34 (d, J = 2.0 Hz, 1 H, H-
5), 7.39 (dd, J1 = 8.5 Hz, J2 = 2.0 Hz, 1 H, H-7), 8.17 (d, J = 8.5 Hz, 1 H, H-8). 
13C NMR 
(100 MHz, CDCl3): δ (ppm) 13.94 (C-5’), 22.35 (C-4’), 26.50 (C-2’), 31.14 (C-3’), 33.55 (C-
1’), 102.02 (C-4), 118.41 (C-8a), 124.56 (C-5), 128.02 (C-7), 131.20 (C-8), 139.00 (C-4a), 26 V.  Hampl  et al.:  
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141.34 (C-6), 159.86 (C-3), 162.30 (C-1). HRMS: Calcd. for C14H15O2Cl: 250.0761. Found: 
250.0834. Anal. Calcd. for C14H15O2Cl: C, 67.07; H, 6.03. Found: C: 67.93; H: 6.90. 
5-Methyl-3-pentyl-1H-isochromen-1-one (2d) 
Prepared following General procedure I from 0.524 g (2.0 mmol) 2-iodo-3-methylbenzoic 
acid to give 80 mg (18 %) as a yellow oil. MS (m/z, %): 230 ([M]
+·, 48), 174 (37), 132 (100), 
103 (13). IR (KBr), ν (cm
−1): 2927, 2857, 1724, 1652, 1465, 1380, 1270, 1174, 1058, 1022, 
759, 705, 584. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.81 (t, J = 7.6 Hz, 3 H, H-5’), 1.29 (m, 
4 H, H-3’, H-4’), 1.65 (m, 2 H, H-2’), 2.39 (s, 3 H, Ar-CH3), 2.47 (t, J = 7.6 Hz, 3 H, H-1’), 
6.29 (s, 1 H, H-4), 7.26 (dd, J1 = J2 = 7.8 Hz, 1 H, H-7), 7.44 (d, J = 7.8 Hz, 1 H, H-6), 8.05 
(d, J = 7.8 Hz, 1 H, H-8). 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.96 (C-5’), 18.72 (Ar-
CH3), 22.45 (C-4’), 26.78 (C-2’), 31.21 (C-3’), 33.86 (C-1’), 99.66 (C-4), 120.12 (C-4a), 
127.00 (C-7), 127.36 (C-8), 132.57 (C-8a), 135.90 (C-6), 136.32 (C-5), 157.89 (C-3), 
163.52 (C-1). HRMS: Calcd. for C15H18O2: 230.1307. Found: 230.1317. Anal. Calcd. for 
C15H18O2: C, 77.38; H, 9.74. Found: C: 77.17; H, 8.03. 
(±)-3-Pentylisochroman-1-one 
(rac-(3R)-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3a) 
Following General procedure II from 200 mg (0.925 mmol) 3-pentylisochromen-1-one (2a) 
using 20 mg Pd on charcoal (10 %) to give 160 mg (80 %) as a colourless oil. MS (m/z, 
%): 218 ([M]
+·, 12), 147 (72), 118 (100), 105 (28). IR (KBr), ν (cm
−1): 2943, 2855, 1705, 
1650, 1455, 1170, 765, 701, 593. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.2 Hz, 
3 H, H-5´), 1.34 (m, 4 H, H-3’, H-4’), 1.47 (m, 1 H, H-2’), 1.58 (m, 1 H, H-2’), 1.72 (m, 1 H, 
H-1’), 1.88 (m, 1 H, H-1’), 2.94 (m, 2 H, H-4), 4.52 (m, 1 H, H-3), 7.24 (dd, J1 = J2 = 7.6 Hz, 
1 H, H-5), 7.38 (dd, J1 = J2 = 7.6 Hz, 1 H, H-6), 7.52 (ddd, J1 = J2 = 7.6 Hz, J3= 1.4 Hz, 1 
H, H-7), 8.09 (d, J = 7.6 Hz, 1 H, H-8). 
13C NMR (100 MHz, CDCl3): δ (ppm) 14.01 (C-5´), 
22.53 (C-4’), 24.60 (C-2’), 31.57 (C-3’), 33.21 (C-4), 34.94 (C-1’), 77.39 (C-3), 125.23 (C-
4a), 127.37 (C-5), 127.58 (C-6), 130.23 (C-8), 133.64 (C-7) 139.25 (C-8a), 165.74 (C-1). 
HRMS: Calcd. for C14H18O2: 218.1307. Found: 218.1286. Anal. Calcd. for C14H18O2: C, 
77.38; H, 9.74. Found: C, 77.17; H, 8.03. 
(±)-8-Fluoro-3-pentylisochroman-1-one 
(rac-(3R)-8-fluoro-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3b) 
Following General procedure II from  28 mg (0.12 mmol) 8-fluoro-3-pentylisochromen-
1-one (2b) using 5 mg Pd on charcoal (10 %) to give 25 mg (89 %) as a pale yellow oil. IR 
(KBr), ν (cm
−1): 3456, 2955, 2928, 2858, 1731, 1660, 1615, 1582, 1470, 1378, 1358, 1253, 
1099, 1057, 1031, 803, 780, 727, 690. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.1 
Hz, 3 H, H-5’), 1.33 (m, 4 H, H-3’, H-4’), 1.45 (m, 1 H, H-2’), 1.57 (m, 1 H, H-2’), 1.71 (m, 1 
H, H-1’), 1.87 (m, 1 H, H-1’), 2.94 (m, 2 H, H-4), 4.48 (m, 1 H, H-3), 7.09 (m, 2 H, H-5 and 
H-7), 7.50 (m, 1 H, H-6). 
13C-NMR (125 MHz, CDCl3) δ (ppm): 14.04 (C-5’), 22.53 (C-4’), 
24.55 (C-2’), 31.58 (C-4), 33.65 (d, J = 2.4 Hz, C-4), 34.73 (C-1’), 78.53 (C-3), 113.87 (d, J 
= 6.9 Hz, C-8a), 116.01 (d, J = 21.6 Hz, C-7), 123.07 (d, J = 3.8 Hz, C-5), 134.95 (d, J = 
10.0 Hz, C-6), 141.90 (C-4a), 161.43 (C-1), 162.99 (d, J = 264.8 Hz, C-8). HRMS: Calcd. 
for C15H20O2: 236.1213. Found: 236.1195.  
   Substituted Isocoumarins and Dihydroisocoumarins  27 
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(±)-5-Methyl-3-pentyl-isochroman-1-one 
(rac-(3R)-5-methyl-3-pentyl-3,4-dihydro-1H-isochromen-1-one, 3d) 
Following General procedure II from 40 mg (0.17 mmol) 5-methyl-3-pentylisochromen-1-
one (2d) using 4 mg Pd on charcoal (10 %) to give 35 mg (89 %) as a colourless oil. MS 
(m/z, %): 232 ([M]
+·, 21), 161 (63), 133 (100), 105 (29). IR (KBr), ν (cm
−1): 2956, 2929, 
2859, 1774, 1745, 1660, 1614, 1567, 1475, 1376, 1315, 1253, 1157, 1105, 1012, 831, 
808, 777, 728, 688, 669. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.91 (t, J = 7.0 Hz, 3 H, H-
5’), 1.34 (m, 4 H, H-3’, H-4’), 1.49 (m, 1 H, H-2’), 1.59 (m, 1 H, H-2’), 1.74 (m, 1 H, H-1’), 
1.89 (m, 1 H, H-1’), 2.32 (s, 3 H, Ar-CH3), 2.77 (dd, J1 = 3.3 Hz, J2 = 16.6 Hz, 1 H, H-4), 
2.92 (dd, J1 = 3.3 Hz, J2 = 16.6 Hz, 1 H, H-4), 4.48 (m, 1 H, H-3), 7.27 (dd, J1 = J2 = 7.7 
Hz, 1 H, H-7), 7.39 (d, J = 7.7 Hz, 1 H, H-6), 7.96 (d, J = 7.7 Hz, 1 H, H-8). 
13C-NMR (125 
MHz, CDCl3) δ (ppm): 13.98 (C-5’), 18.85 (Ar-CH3), 22.49 (C-4’), 24.62 (C-2’), 30.23 (C-4), 
31.57 (C-3’), 35.08 (C-1’), 77.25 (C-3), 125.20 (C-4a), 126.93 (C-7), 128.07 (C-8), 134.94 
(C-6), 135.00 (C-8a), 137.78 (C-5), 166.08 (C-1). HRMS: Calcd. for C15H20O2: 232.14633. 
Found: 232.14310.  
Methyl 2-(hept-1-yn-1-yl)benzoate (4) 
2.62 g (10.0 mmol) methyl 2-iodobenzoate, 0.96 g (10.0 mmol) hept-1-yne, 200 mg (2.4 
mmol) CuI and 400 mg (0.6 mmol) PdCl2(PPh3)2 were dissolved in 20 mL N-ethyl-
N,N-dimethylamine and the solution was stirred for 12 h at room temperature. The solvent 
was evaporated and the residue was quenched with 20 mL 5% aqueous Na2SO3-solution. 
The mixture was extracted with diethyl ether (3 x 25 mL) and the combined organic layers 
were dried over Na2SO4. The solvent was evaporated and the residue was purified by FCC 
(isohexane/ethyl acetate 5:1) to give 740 mg (32 %) of 4 as a pale brown oil. MS (m/z, %): 
230 ([M]
+·, 22), 215 (36), 174 (100), 159 (72), 133 (96), 115 (42). IR (KBr), ν (cm
−1): 3066, 
2954, 2931, 2859, 2235, 1733, 1596, 1565, 1484, 1446, 1432, 1294, 1274, 1249, 1130, 
1083, 962, 881, 757, 701, 538. 
1H-NMR (400 MHz, CDCl3) δ (ppm): 0.90 (t, J = 7.2 Hz, 3 
H, H-7’), 1.35 (m, 2 H, H-5’), 1.43 (m, 2 H, H-6’), 1.62 (m, 2 H, H-4’), 2.44 (t, J = 7.2 Hz, 2 
H, H-3’), 3.88 (s, 3 H, OCH3), 7.27 (ddd, J1= J2 = 7.8 Hz, J3 = 1.2 Hz, 1 H, H-4), 7.38 (ddd, 
J1= J2 = 7.8 Hz, J3 = 1.2 Hz, 1 H, H-5), 7.48 (dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1 H, H-3), 7.85 
(dd, J1 = 7.8 Hz, J2 = 1.2 Hz, 1 H, H-6). 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.91 (C-7’), 
19.66 (C-6’), 22.16 (C-4’), 28.31 (C-5’), 31.03 (C-3’) 51.93 (OCH3), 79.10 (C-1’), 95.95 (C-
2’), 124.50 (C-2), 127.00 (C-4), 130.03 (C-5), 131.36 (C-3), 131.38 (C-1), 134.10 (C-6), 
166.91 (C=O). Anal. Calcd. for C15H18O2: C, 78.26; H, 7.83. Found: C, 78.69; H, 7.76. 
4-Chloro-3-pentyl-1H-isochromen-1-one (5) 
0.690 g (3.20 mmol) methyl 2-(hept-1-ynyl)-benzoate (4), 0.081 g (6.2 mmol) CuCl2, 0.065 
g (0.30 mmol) N,N-dicyclohexylammonium chloride and 30 mL 1,2-dichloroethane were 
dissolved under N2 atmosphere and heated at 80 °C with stirring. After 12 h the solvent 
was evaporated and the residue was purified by FCC (isohexane/ethyl acetate 10:1) to 
give 580 mg (73 %) of 5 as a pale brown oil. MS (m/z, %): 252 ([M]
+·, 31), 250 ([M]
+·, 100), 
215 (18), 194 (69), 165 (26), 159 (51), 152 (43). IR (KBr), ν (cm
−1): 3072, 3035, 2956, 
2931, 2859, 1745, 1631, 1602, 1567, 1479, 1465, 1319, 1288, 1052, 1031, 975, 964, 925. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.90 (t, J = 7.7 Hz, 3 H, H-5’), 1.37 (m, 4 H, H-3’, H-
4’), 1.73 (m, 2 H, H-2’), 2.75 (t, J = 7.7 Hz, 2 H, H-1’), 7.53 (ddd, J1= J2 = 7.8 Hz, J3 = 1.2 
Hz, 1 H, H-7), 7.79 (m, 2 H, H-5, H-6), 8.26 (d, J = 7.8 Hz, 1 H, H-8). 
13C NMR (100 MHz, 
CDCl3): δ (ppm) 13.89 (C-5’), 22.30 (C-4’), 26.41 (C-2’), 31.17 (C-1’, 3’), 110.89 (C-4), 28 V.  Hampl  et al.:  
Sci Pharm. 2011; 79: 21–30 
120.13 (C-8a), 123.14 (C-5), 128.35 (C-7), 129.73 (C-8), 135.17 (C-6), 135.54 (C-4a), 
154.66 (C-3), 161.31 (C-1). Anal. Calcd. for C14H15O2Cl: C, 67.07; H, 6.03. Found: C, 
67.24; H, 6.45. 
MTT assay 
A solution of the substance in dimethyl sulfoxide (1 μl, concentrations in the range from 
10
−9 to 10
−4 mol/l) was incubated with 99 μl of a suspension of HL 60 cells (9 × 10
5 
cells/ml) in RPMI 1640 medium (PAA Laboratories) with 10% FKS in 96 well plates for 24 
h. Then, 10 μl of a solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) in PBS (5 mg/ml) were added and the plate was incubated for another 2 h. The 
cells were quenched with 190 μl dimethyl sulfoxide and after a few min, the plates were 
evaluated on a Dynatech MRX at a wavelength of 570 nm; the reference wavelength was 
630 nm [18]. The experiments were performed in triplicate. 
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